Cervical Cancer Risk in Women with HIV: A Growing Concern and Evolving Screening Strategies
A recent systematic review, published in 2026, highlights a clear age-related increase in cervical intraepithelial neoplasia (CIN) among women living with HIV. The research, analyzing data from over 72,300 women across seven countries, reveals that those aged 45-49 are at the highest risk of developing precancerous changes in the cervix.
The Interplay of HIV and HPV
Women living with HIV face a significantly elevated risk of cervical cancer and more frequent HPV infections compared to their HIV-negative counterparts. This increased vulnerability stems from the immune suppression associated with HIV, which allows HPV – the primary cause of cervical cancer – to persist and progress more readily.
The study utilized data from Burkina Faso, Cameroon, India, Kenya, South Africa, Thailand, and the USA. Researchers employed random-effects models to predict probabilities for cervical cancer screening results, factoring in age, HIV status, and antiretroviral therapy.
Age-Specific Risk and Screening Recommendations
The pooled predicted probability of CIN2 or CIN3 was approximately 6% in young women aged 15-19. However, this figure dramatically increased to around 32.4% in women with HIV aged 20-24. The risk continued to climb with age, reaching 58.1% in women aged 45-49, and 55.3% in those 50 and above.
Notably, invasive cervical cancer was uncommon before the age of 30.
These findings directly informed updated recommendations from the World Health Organization (WHO) regarding cervical cancer screening for women living with HIV. The WHO now advises initiating screening at age 25, with regular follow-up screenings every 3-5 years.
WHO’s Global Strategy for Cervical Cancer Elimination
The WHO launched a global strategy in November 2020 aimed at accelerating the elimination of cervical cancer as a public health problem. This ambitious plan sets targets for 2030, including vaccinating 90% of girls with the HPV vaccine by age 15, screening 70% of women with a high-performance test by ages 35 and 45, and ensuring 90% of women with cervical disease receive treatment.
Did you know? HPV DNA can be detected in over 80% of cervical cancer tumors, highlighting the critical link between the virus and the disease.
The Role of Antiretroviral Therapy
Whereas the study didn’t specifically detail the impact of antiretroviral therapy (ART) on CIN risk, it’s understood that effective ART plays a crucial role in restoring immune function and potentially reducing the risk of HPV-related complications. Maintaining a healthy immune system is paramount for women living with HIV.
Future Trends in Cervical Cancer Prevention
The focus is shifting towards more proactive and targeted screening strategies. High-performance tests, such as HPV DNA testing, are becoming increasingly prevalent, offering greater sensitivity and specificity compared to traditional Pap smears. Further research is needed to optimize screening intervals and tailor interventions based on individual risk factors.
FAQ
Q: At what age should women with HIV start cervical cancer screening?
A: The WHO recommends initiating screening at age 25.
Q: How often should women with HIV be screened for cervical cancer?
A: Regular screening every 3-5 years is recommended.
Q: Is HPV vaccination recommended for women living with HIV?
A: Yes, HPV vaccination is a crucial preventative measure, ideally before the onset of sexual activity.
Q: Does HIV status affect the progression of HPV infection?
A: Yes, HIV-related immune suppression increases the risk of persistent HPV infection and progression to cervical cancer.
Pro Tip: Early detection is key. Don’t delay scheduling your cervical cancer screening, especially if you are living with HIV.
Explore more about opportunistic infections in people with HIV on the NIH website.
Have questions about cervical cancer screening? Share your thoughts in the comments below!
